Sanofi-Aventis forms targeted oncology partnership with Ascenta Therapeutics
This article was originally published in Scrip
Sanofi-Aventis has strengthened its commitment to the busy field of targeted oncology therapies by signing an exclusive global collaboration and licensing agreement with Ascenta Therapeutics, a US biopharmaceutical company focused on orally active small-molecule drugs that restore apoptosis or programmed cell death.
You may also be interested in...
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.
Novartis' efforts to revive its COX-2 inhibitor lumiracoxib under a new brand name, and with the risk of hepatotoxicity that killed the drug in its original incarnation muted by a companion diagnostic, have stumbled in Europe after the company withdrew an application for centralised approval of what is now known as Joicela.
Crystallics, a new contract research organisation specialising in solid-state research and pre-formulation activities for the pharmaceutical, biotechnology and agrochemical industries, has been established in the Netherlands through a management buyout of the former Avantium Pharma business from its parent company, Avantium Holding.